Author: OurCrowd

[DailyPay in DailyPay] DailyPay ranked number 185 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Nov 21, 2024 |

NEW YORK, NY, UNITED STATES, November 21, 2024 /EINPresswire.com/ — DailyPay, a worktech company and the leading provider of earned wage access (EWA), today announced it ranked 185 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. DailyPay grew 640% over the last 3 years. Read...

Read More

[Biolojic in GlobeNewswire] Biolojic Design appoints Neal Curran as Chief Business Officer

Nov 21, 2024 |

REHOVOT, Israel and WASHINGTON, Nov. 21, 2024 (GLOBE NEWSWIRE) — Biolojic Design, a biotechnology company that uses computational biology and artificial intelligence (AI) to transform antibodies into programmable, intelligent medicines, today announced the appointment of Neal Curran as Chief Business Officer. Mr. Curran joins Biolojic Design with extensive experience in business development in the biopharmaceutical industry and comes to the company as it expands its business and development activities in the U.S. Read...

Read More

[Arrow Global in Alternative Credit Investor] Arrow Global reports record origination as funds under management hit €10.5bn

Nov 21, 2024 |

Arrow Global has reported record origination volumes in the third quarter of this year, while funds under management (FUM) rose to €10.5bn (£8.7bn). The European asset manager, which focuses on private credit and real estate, said that it has deployed €1.25bn over the year to date, €719m of which occurred during the third quarter, with a strong pipeline heading into the fourth quarter of the year. Read...

Read More

[Alloy Therapeutics in BusinessWire] Alloy Therapeutics signs collaboration and license agreement with Takeda to develop cell therapy platform

Nov 20, 2024 |

TOKYO & BOSTON–(BUSINESS WIRE)–Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK “Takeda”) to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). Alloy will focus on accelerating the development of key therapies to overcome solid and hematological malignancies. Read...

Read More